信邦制药2024年净利降至近6年最低，营业外支出增长488%

Core Viewpoint - Xinfang Pharmaceutical (SZ002390) reported a decline in both revenue and net profit for the year 2024, indicating significant challenges in its business operations [1][3]. Financial Performance - In 2024, Xinfang Pharmaceutical's operating revenue was 6.03 billion yuan, a decrease of 6.63% compared to 2023 [2][3]. - The net profit attributable to shareholders was 101 million yuan, down 64.7% year-on-year, marking the lowest level in nearly six years [2][3]. - The net profit after deducting non-recurring gains and losses was 165 million yuan, a decline of 38.29% from the previous year [2][3]. - The net cash flow from operating activities was 635 million yuan, down 19.69% year-on-year [2][3]. - Basic and diluted earnings per share were both 0.05 yuan, a decrease of 66.67% compared to 0.15 yuan in 2023 [2][3]. Asset and Equity Position - Total assets at the end of 2024 were approximately 9.03 billion yuan, a decrease of 2.34% from the previous year [2][3]. - The net assets attributable to shareholders were about 6.71 billion yuan, down 2.08% year-on-year [2][3]. Segment Performance - The pharmaceutical distribution segment generated 4.75 billion yuan in revenue, a decline of 10.03%, with a gross margin of 9.17% [3][4]. - The medical services segment reported revenue of 1.64 billion yuan, down 8.48%, with a gross margin of 9.55% [3][4]. - The traditional Chinese medicine manufacturing segment achieved revenue of 939 million yuan, an increase of 11.28%, but with a gross margin of 47.89%, down 1.83% [3][4]. Non-Recurring Gains and Losses - In 2024, non-recurring losses amounted to approximately 63.94 million yuan, compared to a gain of 19.33 million yuan in the previous year [5][6]. - The largest component of non-recurring losses was from "other operating income and expenses," totaling 67 million yuan [5][6]. Investment and Other Income - Investment income for the year was approximately 1.30 million yuan, a significant increase of 264.84% compared to the previous year [7]. - Operating expenses decreased by 43.07% in the first three quarters of 2024, indicating a potential improvement in cost management [6][7].